John Trojanowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6816703/publications.pdf

Version: 2024-02-01

1,007	183,925	196	382
papers	citations	h-index	g-index
		26	64

1086	1086	1086	81750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Î±-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.	13.7	7,181
2	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science, 2006, 314, 130-133.	6.0	5,422
3	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
4	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
5	Association of missense and 5â€²-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.	13.7	3,333
6	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
7	Neurodegenerative Tauopathies. Annual Review of Neuroscience, 2001, 24, 1121-1159.	5.0	2,416
8	Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. New England Journal of Medicine, 2001, 344, 710-719.	13.9	2,253
9	Pathological Î±-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. Science, 2012, 338, 949-953.	6.0	2,024
10	National Institute on Agingâ€“Alzheimerâ€™s Association guidelines for the neuropathologic assessment of Alzheimerâ€™s disease: a practical approach. Acta Neuropathologica, 2012, 123, 1-11.	3.9	2,002
11	National Institute on Agingâ€“Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 1-13.	0.4	1,968
12	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
13	Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience, 2007, 8, 663-672.	4.9	1,866
14	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413.	2.8	1,803
15	Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron, 2007, 53, 337-351.	3.8	1,696
16	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
17	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
18	Oxidative Damage Linked to Neurodegeneration by Selective alpha -Synuclein Nitration in Synucleinopathy Lesions. Science, 2000, 290, 985-989.	6.0	1,498

#	Article	IF	Citations
19	Demonstrated brain insulin resistance in Alzheimerâ€™s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 2012, 122, 1316-1338.	3.9	1,431
20	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	2.8	1,278
21	Exogenous Î±-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. Neuron, 2011, 72, 57-71.	3.8	1,249
22	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature, 2013, 495, 467-473.	13.7	1,249
23	Chaperone Suppression of alpha -Synuclein Toxicity in a Drosophila Model for Parkinson's Disease. Science, 2002, 295, 865-868.	6.0	1,206
24	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 2010, 466, 1069-1075.	13.7	1,117
25	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	3.8	1,100
26	Neuronal Î±-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human Î±-Synuclein. Neuron, 2002, 34, 521-533.	3.8	1,094
27	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
28	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	4.9	1,039
29	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	3.9	978
30	Intracerebral inoculation of pathological Î±-synuclein initiates a rapidly progressive neurodegenerative Î±-synucleinopathy in mice. Journal of Experimental Medicine, 2012, 209, 975-986.	4.2	910
31	Harnessing neuroplasticity for clinical applications. Brain, 2011, 134, 1591-1609.	3.7	907
32	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	3.7	873
33	Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1095-1097.	0.9	872
34	A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of Î±-Synuclein Is Essential for Filament Assembly. Journal of Biological Chemistry, 2001, 276, 2380-2386.	1.6	865
35	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	3.9	854
36	Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron, 1993, 10, 1089-1099.	3.8	845

#	Article	IF	Citations
37	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations. Annals of Neurology, 2007, 61, 427-434.	2.8	840
38	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science, 2015, 347, 1436-1441.	6.0	823
39	Stages of pTDPâ€43 pathology in amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 20-38.	2.8	820
40	Molecular basis of phenotypic variability in sporadc creudeldt-jakob disease. Annals of Neurology, 1996, 39, 767-778.	2.8	819
41	Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain, 2013, 136, 28-42.	3.7	819
42	A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica, 2011, 122, 111-113.	3.9	817
43	Synucleins Are Developmentally Expressed, and Î±-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons. Journal of Neuroscience, 2000, 20, 3214-3220.	1.7	795
44	Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein. Science, 2003, 300, 636-640.	6.0	791
45	Exogenous Î±-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20051-20056.	3.3	783
46	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
47	Parkinson's disease dementia: convergence of Î±-synuclein, tau and amyloid-Î² pathologies. Nature Reviews Neuroscience, 2013, 14, 626-636.	4.9	673
48	Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. Neuron, 2013, 79, 1094-1108.	3.8	673
49	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurology, The, 2008, 7, 409-416.	4.9	636
50	Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble ?-synuclein. Annals of Neurology, 1998, 44, 415-422.	2.8	633
51	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Medicine, 2004, 10, 1055-1063.	15.2	624
52	Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nature Reviews Neuroscience, 2015, 16, 109-120.	4.9	611
53	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimerâ€™s Coordinating Centre. Brain, 2013, 136, 2697-2706.	3.7	609
54	Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron, 1994, 13, 989-1002.	3.8	589

#	Article	IF	Citations
55	Increase of Brain Oxidative Stress in Mild Cognitive Impairment. Archives of Neurology, 2002, 59, 972.	4.9	574
56	Distinct Î±-Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell, 2013, 154, 103-117.	13.5	574
57	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nature Reviews Neuroscience, 2012, 13, 38-50.	4.9	568
58	Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform. Neuron, 1999, 24, 751-762.	3.8	564
59	The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature Communications, 2011, 2, 252.	5.8	554
60	Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy. Journal of Neuroscience, 2013, 33, 1024-1037.	1.7	548
61	Large-scale proteomic analysis of Alzheimerâ€™s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	15.2	547
62	Gene expression changes in the course of normal brain aging are sexually dimorphic. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15605-15610.	3.3	520
63	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
64	Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation. Journal of Biological Chemistry, 2008, 283, 13302-13309.	1.6	509
65	Experimental Brain Injury Induces Regionally Distinct Apoptosis during the Acute and Delayed Post-Traumatic Period. Journal of Neuroscience, 1998, 18, 5663-5672.	1.7	495
66	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	9.4	494
67	The Levels of Soluble versus Insoluble Brain AÎ² Distinguish Alzheimer's Disease from Normal and Pathologic Aging. Experimental Neurology, 1999, 158, 328-337.	2.0	490
68	Lewy Bodies Contain Altered Î±-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. American Journal of Pathology, 1998, 153, 1365-1370.	1.9	484
69	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
70	Mutant and Wild Type Human Î±-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro. Journal of Biological Chemistry, 1999, 274, 7619-7622.	1.6	478
71	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
72	Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathologica, 2009, 117, 137-149.	3.9	466

#	Article	IF	Citations
73	Synergistic Interactions between AÎ², Tau, and Î±-Synuclein: Acceleration of Neuropathology and Cognitive Decline. Journal of Neuroscience, 2010, 30, 7281-7289.	1.7	462
74	Cellular milieu imparts distinct pathological Î±-synuclein strains in Î±-synucleinopathies. Nature, 2018, 557, 558-563.	13.7	457
75	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	3.7	455
76	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	3.7	448
77	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	1.9	446
78	Frontotemporal dementia: Clinicopathological correlations. Annals of Neurology, 2006, 59, 952-962.	2.8	444
79	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	5.8	444
80	Synucleinopathies. Archives of Neurology, 2001, 58, 186.	4.9	437
81	Mechanisms of Parkinson's Disease Linked to Pathological Î±-Synuclein: New Targets for Drug Discovery. Neuron, 2006, 52, 33-38.	3.8	437
82	Genetic evidence for the involvement of ? in progressive supranuclear palsy. Annals of Neurology, 1997, 41, 277-281.	2.8	433
83	Amyloid-Î² plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nature Medicine, 2018, 24, 29-38.	15.2	433
84	Amyotrophic lateral sclerosisâ€”a model of corticofugal axonal spread. Nature Reviews Neurology, 2013, 9, 708-714.	4.9	432
85	Induction of Î±-Synuclein Aggregation by Intracellular Nitrative Insult. Journal of Neuroscience, 2001, 21, 8053-8061.	1.7	412
86	Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine, 2008, 14, 507-509.	15.2	410
87	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
88	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	2.8	401
89	Progressive Atrophy and Neuron Death for One Year Following Brain Trauma in the Rat. Journal of Neurotrauma, 1997, 14, 715-727.	1.7	398
90	Increased F₂â€isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidationin vivo. FASEB Journal, 1998, 12, 1777-1783.	0.2	396

#	Article	IF	Citations
91	TAR DNA-binding protein 43 in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 211-220.	4.9	396
92	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€"An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.4	396
93	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	4.9	394
94	Neuroinflammation and Oxidation/Nitration of Î±-Synuclein Linked to Dopaminergic Neurodegeneration. Journal of Neuroscience, 2008, 28, 7687-7698.	1.7	385
95	Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery, 2009, 8, 783-793.	21.5	383
96	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
97	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	3.9	378
98	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	3.9	377
99	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 227-231.	3.3	374
100	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	4.5	374
101	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
102	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
103	Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 2011, 70, 327-340.	2.8	367
104	Phosphorylated Î±-Synuclein Is Ubiquitinated in Î±-Synucleinopathy Lesions. Journal of Biological Chemistry, 2002, 277, 49071-49076.	1.6	365
105	A yeast functional screen predicts new candidate ALS disease genes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20881-20890.	3.3	365
106	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.4	362
107	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
108	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354

#	Article	IF	Citations
109	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 2012, 33, 1203-1214.e2.	1.5	346
110	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
111	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
112	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. Journal of Clinical Investigation, 2011, 121, 726-738.	3.9	343
113	Cerebrospinal Fluid Tau and Î²-Amyloid. Archives of Neurology, 2003, 60, 1696.	4.9	341
114	Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9980-9985.	3.3	336
115	Total and phosphorylated tau protein as biological markers of Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 30-40.	1.2	330
116	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	1.7	330
117	Protein transmission in neurodegenerative disease. Nature Reviews Neurology, 2020, 16, 199-212.	4.9	330
118	Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies. Journal of Neuropathology and Experimental Neurology, 2008, 67, 555-564.	0.9	328
119	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	1.7	325
120	Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathologica, 2005, 109, 5-13.	3.9	324
121	Therapeutic modulation of eIF2Î± phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nature Genetics, 2014, 46, 152-160.	9.4	321
122	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of Î²â€amyloid. Annals of Neurology, 2013, 74, 826-836.	2.8	320
123	Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau. Journal of Biological Chemistry, 1995, 270, 18917-18922.	1.6	319
124	Association of Cerebrospinal Fluid Î²-Amyloid 1-42, T-tau, P-tau₁₈₁, and Î±-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology, 2013, 70, 1277-87.	4.5	318
125	Repetitive Mild Brain Trauma Accelerates AÎ² Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis. Journal of Neuroscience, 2002, 22, 446-454.	1.7	314
126	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Annals of Neurology, 2000, 48, 77-87.	2.8	310

#	Article	IF	Citations
127	Unique pathological tau conformers from Alzheimerâ€™s brains transmit tau pathology in nontransgenic mice. Journal of Experimental Medicine, 2016, 213, 2635-2654.	4.2	310
128	Widespread transneuronal propagation of Î±-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinsonâ€™s disease. Journal of Experimental Medicine, 2016, 213, 1759-1778.	4.2	309
129	Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathologica, 2010, 119, 409-419.	3.9	308
130	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. PLoS Genetics, 2014, 10, e1004606.	1.5	305
131	Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. Journal of Biological Chemistry, 2009, 284, 8516-8524.	1.6	304
132	APOE Ïµ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	4.5	302
133	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
134	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
135	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Annals of Neurology, 2002, 52, 205-210.	2.8	300
136	TDP-43 stage, mixed pathologies, and clinical Alzheimerâ€™s-type dementia. Brain, 2016, 139, 2983-2993.	3.7	298
137	Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies. American Journal of Pathology, 2006, 169, 1343-1352.	1.9	296
138	Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Annals of Neurology, 1995, 38, 649-652.	2.8	293
139	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews Drug Discovery, 2007, 6, 295-303.	21.5	293
140	Misfolded proteinase Kâ€“resistant hyperphosphorylated Î±-synuclein in aged transgenic mice with locomotor deterioration and in human Î±-synucleinopathies. Journal of Clinical Investigation, 2002, 110, 1429-1439.	3.9	292
141	Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.	2.8	289
142	Early Vitamin E supplementation in young but not aged mice reduces AÎ² levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB Journal, 2004, 18, 323-325.	0.2	288
143	Typical and atypical pathology in primary progressive aphasia variants. Annals of Neurology, 2017, 81, 430-443.	2.8	288
144	Î±-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded Î±-Synuclein and Neurodegeneration. Cell Reports, 2014, 7, 2054-2065.	2.9	287

#	Article	IF	Citations
145	Intrastriatal injection of pre-formed mouse Î±-synuclein fibrils into rats triggers Î±-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiology of Disease, 2015, 82, 185-199.	2.1	285
146	Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2008, 173, 182-194.	1.9	284
147	Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain. Journal of Neuroscience, 2017, 37, 11406-11423.	1.7	284
148	Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, R156-R162.	1.4	281
149	Mild head injury increasing the brain's vulnerability to a second concussive impact. Journal of Neurosurgery, 2001, 95, 859-870.	0.9	278
150	Mouse Model of Multiple System Atrophy Î±-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration. Neuron, 2005, 45, 847-859.	3.8	277
151	Neuropathology of synuclein aggregates. Journal of Neuroscience Research, 2000, 61, 121-127.	1.3	275
152	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death and Differentiation, 1998, 5, 832-837.	5.0	272
153	Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	4.5	272
154	Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. Journal of Clinical Investigation, 2020, 130, 1912-1930.	3.9	268
155	Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation. Journal of Cell Biology, 1997, 139, 1307-1315.	2.3	267
156	The cells of origin of the corpus callosum in rat, cat and rhesus monkey. Brain Research, 1974, 74, 149-155.	1.1	266
157	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.4	266
158	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261
159	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
160	Widespread Nitration of Pathological Inclusions in Neurodegenerative Synucleinopathies. American Journal of Pathology, 2000, 157, 1439-1445.	1.9	256
161	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2010, 30, 13861-13866.	1.7	256
162	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 2010, 6, 230-238.	0.4	256

#	Article	IF	Citations
163	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, 2011, 121, 597-609.	3.9	256
164	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
165	Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB Journal, 2002, 16, 1138-1140.	0.2	252
166	The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimerâ€™s and Parkinsonâ€™s diseases1,2 11Guest Editors: Mark A. Smith and George Perry 22This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 32, 1264-1275.	1.3	252
167	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 636-41.	4.9	251
168	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.4	250
169	Aggregation of Neurofilament and Î±-Synuclein Proteins in Lewy Bodies. Archives of Neurology, 1998, 55, 151.	4.9	249
170	Biological markers for therapeutic trials in Alzheimerâ€™s disease. Neurobiology of Aging, 2003, 24, 521-536.	1.5	249
171	Reversible Inhibition of Î±-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations*. Journal of Biological Chemistry, 2005, 280, 21212-21219.	1.6	248
172	Concurrence of Î±-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathologica, 2002, 104, 7-11.	3.9	247
173	Targeting Amyloid-Î² Peptide (AÎ²) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in AÎ² Precursor Protein (APP) Transgenic Mice. Journal of Biological Chemistry, 2006, 281, 4292-4299.	1.6	246
174	Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Human Molecular Genetics, 2012, 21, 2899-2911.	1.4	246
175	Exceptionally low likelihood of Alzheimerâ€™s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	5.8	246
176	Long-Term Accumulation of Amyloid-Î², Î²-Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma. American Journal of Pathology, 2004, 165, 357-371.	1.9	245
177	TDP-43 Mediates Degeneration in a NovelDrosophilaModel of Disease Caused by Mutations in VCP/p97. Journal of Neuroscience, 2010, 30, 7729-7739.	1.7	243
178	Clonal Human (hNT) Neuron Grafts for Stroke Therapy. American Journal of Pathology, 2002, 160, 1201-1206.	1.9	240
179	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica, 2014, 127, 423-439.	3.9	237
180	Dysregulation of the epigenetic landscape of normal aging in Alzheimerâ€™s disease. Nature Neuroscience, 2018, 21, 497-505.	7.1	236

#	Article	IF	Citations
181	Selective Insolubility of Î±-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model. American Journal of Pathology, 2001, 159, 2215-2225.	1.9	235
182	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. Archives of Neurology, 2009, 66, 180-9.	4.9	232
183	The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiology of Disease, 2007, 25, 561-570.	2.1	231
184	An acetylation switch controls TDP-43 function and aggregation propensity. Nature Communications, 2015, 6, 5845.	5.8	231
185	Altered Tau and Neurofilament Proteins in Neuroâ€Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias. Brain Pathology, 1993, 3, 45-54.	2.1	230
186	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	3.7	228
187	A Lack of Amyloid Î² Plaques Despite Persistent Accumulation of Amyloid Î² in Axons of Longâ€Term Survivors of Traumatic Brain Injury. Brain Pathology, 2009, 19, 214-223.	2.1	227
188	The Role of Calpail-Mediated Spectrin Proteolysis in Traumatically Induced Axonal Injury. Journal of Neuropathology and Experimental Neurology, 1999, 58, 365-375.	0.9	226
189	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.	3.7	226
190	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	3.7	226
191	Phosphorylated Î±-Synuclein in Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 121ra20.	5.8	223
192	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
193	Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nature Neuroscience, 2018, 21, 329-340.	7.1	220
194	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathologica, 2015, 129, 469-491.	3.9	218
195	Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathologica, 2015, 130, 643-660.	3.9	215
196	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
197	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
198	Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimerâ€™s disease or corticobasal degeneration brains. Acta Neuropathologica, 2015, 129, 221-237.	3.9	211

#	Article	IF	Citations
199	Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e39216.	1.1	210
200	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	3.9	210
201	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79, 897-905.	1.5	208
202	12/15-Lipoxygenase Is Increased in Alzheimer's Disease. American Journal of Pathology, 2004, 164, 1655-1662.	1.9	207
203	Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases.. FASEB Journal, 1995, 9, 1570-1576.	0.2	206
204	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	3.9	206
205	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.4	205
206	IMPY: an improved thioflavin-T derivative for in vivo labeling of Î²-amyloid plaques. Brain Research, 2002, 956, 202-210.	1.1	204
207	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathologica, 2014, 128, 423-437.	3.9	203
208	Areal and laminar distribution of some pulvinar cortical efferents in rhesus monkey. Journal of Comparative Neurology, 1976, 169, 371-391.	0.9	202
209	TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2007, 66, 177-183.	0.9	201
210	Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2011, 31, 14436-14449.	1.7	201
211	TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age. JAMA Neurology, 2013, 70, 1418.	4.5	200
212	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
213	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2015, 138, 3373-3385.	3.7	200
214	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
215	TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathologica, 2007, 114, 63-70.	3.9	198
216	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics, 2012, 21, 3500-3512.	1.4	198

#	Article	IF	Citations
217	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.4	198
218	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
219	A panel of epitope-specific antibodies detects protein domains distributed throughout human ?-synuclein in lewy bodies of Parkinson's disease. , 2000, 59, 528-533.		197
220	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.5	197
221	Evidence for Ordering of Alzheimer Disease Biomarkers. Archives of Neurology, 2011, 68, 1526.	4.9	195
222	TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways. Journal of Neuroscience, 2012, 32, 11213-11227.	1.7	195
223	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
224	Human fetal hippocampal development: I. Cytoarchitecture, myeloarchitecture, and neuronal morphologic features. Journal of Comparative Neurology, 1996, 367, 274-292.	0.9	193
225	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	192
226	An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimerâ€™s disease. Nature Genetics, 2020, 52, 1024-1035.	9.4	191
227	Prefrontal granular cortex of the rhesus monkey. I. Intrahemispheric cortical afferents. Brain Research, 1977, 132, 209-233.	1.1	190
228	Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by Î±-, Î²-, and Î³-Synuclein Neuropathology. American Journal of Pathology, 2000, 157, 361-368.	1.9	190
229	CSF biomarkers associated with disease heterogeneity in early Parkinsonâ€™s disease: the Parkinsonâ€™s Progression Markers Initiative study. Acta Neuropathologica, 2016, 131, 935-949.	3.9	190
230	Spread of Î±-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nature Neuroscience, 2019, 22, 1248-1257.	7.1	187
231	TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1481.	4.9	186
232	Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Archives of Neurology, 2012, 69, 1310.	4.9	186
233	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	4.1	186
234	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	4.5	185

#	Article	IF	Citations
235	Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies. American Journal of Pathology, 2003, 163, 1021-1031.	1.9	183
236	Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain. Journal of Comparative Neurology, 1995, 357, 618-632.	0.9	182
237	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
238	TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2007, 64, 1388.	4.9	179
239	AÎ² Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. American Journal of Pathology, 2010, 177, 1977-1988.	1.9	179
240	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
241	More than just two peas in a pod: common amyloidogenic properties of tau and Î±-synuclein in neurodegenerative diseases. Trends in Neurosciences, 2004, 27, 129-134.	4.2	177
242	Î±-Synuclein pathology in Parkinsonâ€™s disease and related Î±-synucleinopathies. Neuroscience Letters, 2019, 709, 134316.	1.0	177
243	Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nature Communications, 2018, 9, 4220.	5.8	176
244	â€˜Unfoldingâ€™ pathways in neurodegenerative disease. Trends in Neurosciences, 2003, 26, 407-410.	4.2	174
245	Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. Journal of Neurochemistry, 2009, 110, 1339-1351.	2.1	174
246	Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LCâ€™s afferent and efferent connections. Acta Neuropathologica, 2015, 130, 349-362.	3.9	174
247	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	1.5	174
248	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. Journal of Experimental Medicine, 2018, 215, 2355-2377.	4.2	173
249	APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease. JAMA Neurology, 2014, 71, 1405.	4.5	172
250	Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease. American Journal of Pathology, 2008, 173, 1488-1495.	1.9	171
251	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron, 2017, 95, 297-308.e6.	3.8	171
252	Tau Pathology in a Family with Dementia and a P301L Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 335-345.	0.9	170

#	Article	IF	Citations
253	Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO Journal, 2012, 31, 1241-1252.	3.5	170
254	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
255	Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy. Journal of Neuroscience, 2004, 24, 4657-4667.	1.7	169
256	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. Neuropathology, 2010, 30, 103-112.	0.7	169
257	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiology of Disease, 2015, 73, 83-95.	2.1	168
258	Age-Dependent Induction of Congophilic Neurofibrillary Tau Inclusions in Tau Transgenic Mice. American Journal of Pathology, 2001, 158, 555-562.	1.9	167
259	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. Journal of Neurology, 2009, 256, 1205-1214.	1.8	167
260	Olfactory epithelium amyloidâ€î² and paired helical filamentâ€tau pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 462-469.	2.8	167
261	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.4	167
262	Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration. Journal of Neuroscience, 2005, 25, 3539-3550.	1.7	166
263	The Spectrum of Mutations in Progranulin. Archives of Neurology, 2010, 67, 161-70.	4.9	166
264	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
265	Novel CSF biomarkers for Alzheimerâ€™s disease and mild cognitive impairment. Acta Neuropathologica, 2010, 119, 669-678.	3.9	164
266	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathologica, 2012, 123, 825-839.	3.9	164
267	Altered expression ofbcl-2 andbax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Annals of Neurology, 1996, 40, 379-386.	2.8	163
268	Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathologica, 2017, 134, 65-78.	3.9	163
269	Cerebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology. Biochemical and Biophysical Research Communications, 1997, 236, 262-264.	1.0	162
270	A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiology of Disease, 2009, 34, 417-431.	2.1	162

#	Article	IF	Citations
271	Mechanisms of Cell-to-Cell Transmission of Pathological Tau. JAMA Neurology, 2019, 76, 101.	4.5	162
272	Pathological TDP-43 in parkinsonismâ€“dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathologica, 2007, 115, 133-145.	3.9	161
273	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of Î²-Amyloid 1-42, Total tau, and P-tau₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology. Archives of Neurology, 2011, 68, 1137.	4.9	161
274	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	3.9	161
275	Modeling Parkinsonâ€™s disease pathology by combination of fibril seeds and Î±-synuclein overexpression in the rat brain. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8284-E8293.	3.3	161
276	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
277	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 308-316.	2.8	160
278	P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating. PLoS ONE, 2011, 6, e21050.	1.1	160
279	Longitudinal change in CSF Tau and AÎ² biomarkers for up to 48Âmonths in ADNI. Acta Neuropathologica, 2013, 126, 659-670.	3.9	160
280	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Annals of Neurology, 2001, 49, 165-175.	2.8	159
281	Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. NeuroImage, 2009, 45, 645-655.	2.1	159
282	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimerâ€™s disease and tauopathies. Acta Neuropathologica, 2014, 128, 679-689.	3.9	158
283	GBA Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	2.2	158
284	BACE1 Activity Is Modulated by Cell-Associated Sphingosine-1-Phosphate. Journal of Neuroscience, 2011, 31, 6850-6857.	1.7	157
285	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.4	157
286	High-Contrast InÂVivo Imaging of Tau Pathologies in Alzheimerâ€™s and Non-Alzheimerâ€™s Disease Tauopathies. Neuron, 2021, 109, 42-58.e8.	3.8	157
287	A distinct familial presenile dementia with a novel missense mutation in the tau gene. NeuroReport, 1999, 10, 497-501.	0.6	156
288	The cytoskeleton in neurodegenerative diseases. Journal of Pathology, 2004, 204, 438-449.	2.1	156

#	Article	IF	Citations
289	Modulation of Nuclear Factor-Î¹B Activity by Indomethacin Influences AÎ² Levels but Not AÎ² Precursor Protein Metabolism in a Model of Alzheimer's Disease. American Journal of Pathology, 2004, 165, 2197-2206.	1.9	156
290	Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous Î±-Synuclein Inclusions of Î±-Synucleinopathies. American Journal of Pathology, 2006, 168, 947-961.	1.9	154
291	â€œFatal Attractionsâ€•of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders. Annals of the New York Academy of Sciences, 2000, 924, 62-67.	1.8	154
292	Spread of aggregates after olfactory bulb injection of Î±-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathologica, 2018, 135, 65-83.	3.9	154
293	Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Annals of Neurology, 1997, 41, 200-209.	2.8	153
294	Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies. Journal of Neuroscience, 2008, 28, 12255-12267.	1.7	153
295	Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone. JAMA Neurology, 2013, 70, 462.	4.5	153
296	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 2017, 140, aww339.	3.7	153
297	Cholera toxin and wheat germ agglutinin conjugates as neuroanatomical probes: Their uptake and clearance, transganglionic and retrograde transport and sensitivity. Brain Research, 1982, 243, 215-224.	1.1	152
298	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.9	152
299	Factors affecting AÎ² plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	3.9	151
300	Altered expression of the synuclein family mRNA in Lewy body and Alzheimerâ€™s disease. Brain Research, 2001, 914, 48-56.	1.1	150
301	Brain Trauma Induces Massive Hippocampal Neuron Death Linked to a Surge in Î²-Amyloid Levels in Mice Overexpressing Mutant Amyloid Precursor Protein. American Journal of Pathology, 1998, 153, 1005-1010.	1.9	148
302	Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Annals of Neurology, 2010, 68, 535-540.	2.8	148
303	Association Between In Vivo Fluorine 18â€“Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology. Archives of Neurology, 2011, 68, 1398.	4.9	148
304	Distinct cleavage patterns of normal and pathologic forms of Î±-synuclein by calpain I in vitro. Journal of Neurochemistry, 2003, 86, 836-847.	2.1	147
305	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry, 2004, 90, 758-764.	2.1	147
306	Horseradish peroxidase (HRP) conjugates of cholera toxin and lectins are more sensitive retrogradely transported markers than free HRP. Brain Research, 1982, 231, 33-50.	1.1	146

#	Article	IF	Citations
307	Deep clinical and neuropathological phenotyping of <scp>P</scp>ick disease. Annals of Neurology, 2016, 79, 272-287.	2.8	146
308	Conjugates of horseradish peroxidase (HRP) with cholera toxin and wheat germ agglutinin are superior to free HRP as orthogradely transported markers. Brain Research, 1981, 223, 381-385.	1.1	145
309	Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. , 2000, 88, 2154-2163.		145
310	Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 2011, 56, 52-60.	2.1	144
311	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
312	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. Archives of Neurology, 2001, 58, 383-7.	4.9	143
313	Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration. Neuron, 2002, 35, 433-446.	3.8	142
314	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	2.8	142
315	Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2. Journal of Neuroscience, 2005, 25, 689-698.	1.7	141
316	Cognitive decline and reduced survival inC9orf72expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 163-169.	0.9	141
317	Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. Cell Reports, 2016, 16, 3373-3387.	2.9	141
318	Amyloid-Beta (AÎ²) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with AÎ² Pathology. Neuron, 2020, 105, 260-275.e6.	3.8	141
319	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. Journal of Biological Chemistry, 2003, 278, 48120-48128.	1.6	140
320	Improvement of cognitive deficits and decreased cholinergic neuronal cell loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury. Journal of Neurosurgery, 1997, 86, 511-518.	0.9	139
321	Parkinson's Disease and Related Î±â€Synucleinopathies Are Brain Amyloidoses. Annals of the New York Academy of Sciences, 2003, 991, 107-110.	1.8	139
322	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-Î²1â€“42 and Ï„ Proteins as Alzheimer Disease Biomarkers. Clinical Chemistry, 2013, 59, 903-916.	1.5	139
323	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	3.9	139
324	Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. Frontiers in Aging Neuroscience, 2020, 12, 80.	1.7	139

#	Article	IF	Citations
325	Lewy Body Pathology in Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 225-232.	1.1	138
326	Two German Kindreds With Familial Amyotrophic Lateral Sclerosis Due to TARDBP Mutations. Archives of Neurology, 2008, 65, 1185-9.	4.9	138
327	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	2.4	138
328	Prefrontal granular cortex of the rhesus monkey. II. Interhemispheric cortical afferents. Brain Research, 1977, 132, 235-246.	1.1	137
329	Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells). Journal of Neuroscience, 1997, 17, 5726-5737.	1.7	137
330	Signature Tau Neuropathology in Gray and White Matter of Corticobasal Degeneration. American Journal of Pathology, 2002, 160, 2045-2053.	1.9	136
331	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Movement Disorders, 2018, 33, 771-782.	2.2	136
332	Characterizing the human hippocampus in aging and Alzheimerâ€™s disease using a computational atlas derived from ex vivo MRI and histology. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4252-4257.	3.3	136
333	Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of Î±-Synuclein Permutations in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 830-841.	0.9	135
334	The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacological Research, 2011, 63, 341-351.	3.1	135
335	BACE overexpression alters the subcellular processing of APP and inhibits Aî² deposition in vivo. Journal of Cell Biology, 2005, 168, 291-302.	2.3	132
336	Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain, 2014, 137, 2578-2587.	3.7	132
337	Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurology, 2016, 73, 733.	4.5	131
338	â€œNew Old Pathologiesâ€• AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). Journal of Neuropathology and Experimental Neurology, 2016, 75, 482-498.	0.9	130
339	Ubiquitination of Î±-Synuclein Is Not Required for Formation of Pathological Inclusions in Î±-Synucleinopathies. American Journal of Pathology, 2003, 163, 91-100.	1.9	129
340	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Research and Therapy, 2017, 9, 89.	3.0	129
341	Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation. Journal of Biological Chemistry, 2013, 288, 11024-11037.	1.6	128
342	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging, 2010, 31, 1284-1303.	1.5	127

#	Article	IF	Citations
343	RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathologica, 1998, 96, 487-494.	3.9	126
344	Protein Accumulation in Traumatic Brain Injury. NeuroMolecular Medicine, 2003, 4, 59-72.	1.8	126
345	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 2011, 69, 655-663.	2.8	126
346	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	1.7	126
347	?-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. Journal of Neuroscience Research, 2000, 62, 9-14.	1.3	125
348	A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. Journal of Neurochemistry, 2003, 86, 1359-1368.	2.1	124
349	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. PLoS ONE, 2015, 10, e0125614.	1.1	124
350	In VivoPositron Emission Tomographic Imaging of Glial Responses to Amyloid-Î² and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders. Journal of Neuroscience, 2011, 31, 4720-4730.	1.7	123
351	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	3.9	123
352	Pathological Î±-synuclein distribution in subjects with coincident Alzheimerâ€™s and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	3.9	123
353	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€“42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
354	Corticothalamic neurons and thalamocortical terminal fields: An investigation in rat using horseradish peroxidase and autoradiography. Brain Research, 1975, 85, 385-401.	1.1	121
355	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	2.8	121
356	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Human Molecular Genetics, 2008, 17, 1349-1362.	1.4	121
357	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology, 2017, 89, 1959-1969.	1.5	121
358	Transmission of tauopathy strains is independent of their isoform composition. Nature Communications, 2020, 11, 7.	5.8	121
359	The disordered neuronal cytoskeleton in Alzheimer's disease. Current Opinion in Neurobiology, 1992, 2, 653-656.	2.0	120
360	Tau and Axonopathy in Neurodegenerative Disorders. NeuroMolecular Medicine, 2002, 2, 131-150.	1.8	120

#	Article	IF	Citations
361	Enhanced Neurofibrillary Tangle Formation, Cerebral Atrophy, and Cognitive Deficits Induced by Repetitive Mild Brain Injury in a Transgenic Tauopathy Mouse Model. Journal of Neurotrauma, 2005, 22, 1134-1141.	1.7	120
362	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	3.7	118
363	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
364	Pesticide Exposure Exacerbates Î±-Synucleinopathy in an A53T Transgenic Mouse Model. American Journal of Pathology, 2007, 170, 658-666.	1.9	117
365	Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathologica, 1996, 91, 475-481.	3.9	116
366	Î±-Internexin Is Present in the Pathological Inclusions of Neuronal Intermediate Filament Inclusion Disease. American Journal of Pathology, 2004, 164, 2153-2161.	1.9	116
367	Extensive FUSâ€Immunoreactive Pathology in Juvenile Amyotrophic Lateral Sclerosis with Basophilic Inclusions. Brain Pathology, 2010, 20, 1069-1076.	2.1	116
368	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Annals of Neurology, 2013, 74, 119-127.	2.8	116
369	Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders. Journal of Comparative Neurology, 1991, 310, 365-376.	0.9	115
370	Tau and Î±-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam. American Journal of Pathology, 2002, 160, 1725-1731.	1.9	115
371	TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without Amyloidosis. NeuroSignals, 2008, 16, 41-51.	0.5	115
372	Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs WithoutGBAMutations. JAMA Neurology, 2013, 70, 852.	4.5	115
373	Sex and APOE Îµ4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	5.8	115
374	Nerve Growth Factor Induces Apoptosis in Human Medulloblastoma Cell Lines that Express TrkA Receptors. Journal of Neuroscience, 1997, 17, 530-542.	1.7	114
375	Heterogeneity of neuroanatomical patterns in prodromal Alzheimerâ€™s disease: links to cognition, progression and biomarkers. Brain, 2017, 140, aww319.	3.7	114
376	Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology, 2017, 88, 2276-2284.	1.5	114
377	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
378	Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. Journal of Biological Chemistry, 2019, 294, 12754-12765.	1.6	114

#	Article	IF	Citations
379	Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell, 2022, 185, 712-728.e14.	13.5	114
380	TDP-43: a novel neurodegenerative proteinopathy. Current Opinion in Neurobiology, 2007, 17, 548-555.	2.0	113
381	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimer's Research and Therapy, 2013, 5, 8.	3.0	113
382	Expression of the Small Heat-Shock Protein Î±B-Crystallin in Tauopathies with Glial Pathology. American Journal of Pathology, 2004, 164, 155-166.	1.9	112
383	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. NeuroImage: Clinical, 2014, 4, 164-173.	1.4	112
384	Non-Alzheimerâ€™s contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathologica, 2018, 136, 377-388.	3.9	112
385	IBOX(2-(4â€²-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nuclear Medicine and Biology, 2001, 28, 887-894.	0.3	111
386	Chronic traumatic encephalopathy â€” confusion and controversies. Nature Reviews Neurology, 2019, 15, 179-183.	4.9	111
387	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	15.2	111
388	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE, 2017, 12, e0175674.	1.1	110
389	Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes. Journal of Neuroscience, 2006, 26, 644-654.	1.7	109
390	A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain, 2010, 133, 1391-1402.	3.7	109
391	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
392	Degradative organelles containing mislocalized Î±- and Î²-synuclein proliferate in presenilin-1 null neurons. Journal of Cell Biology, 2004, 165, 335-346.	2.3	108
393	Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies. Journal of Neuroscience, 2005, 25, 9434-9443.	1.7	108
394	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.9	108
395	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. Acta Neuropathologica, 2019, 138, 389-399.	3.9	108
396	Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathologica, 2005, 110, 547-556.	3.9	107

#	Article	IF	Citations
397	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	3.9	107
398	Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathologica, 1996, 91, 269-277.	3.9	106
399	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewyâ€Related Pathology in the Dementia Patient. Brain Pathology, 2008, 18, 220-224.	2.1	106
400	Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments. Journal of Alzheimer's Disease, 2008, 14, 393-399.	1.2	106
401	Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies. Journal of Comparative Neurology, 1991, 309, 150-160.	0.9	105
402	Â-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies. Journal of Neuroscience, 2011, 31, 10076-10087.	1.7	105
403	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 123, 395-407.	3.9	104
404	Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies. American Journal of Pathology, 2013, 183, 344-351.	1.9	104
405	Native and derivatized lectins for in vivo studies of neuronal connectivity and neuronal cell biology. Journal of Neuroscience Methods, 1983, 9, 185-204.	1.3	102
406	Lewy Bodies in the Amygdala. Archives of Neurology, 2004, 61, 1915-9.	4.9	102
407	Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. NeuroImage, 2009, 46, 394-410.	2.1	102
408	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	3.9	102
409	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimerâ€™s Disease. Cell Reports Medicine, 2020, 1, 100138.	3.3	102
410	Amyloid Î²-Protein (AÎ²) 1â€“40 But Not AÎ²1â€“42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain. Journal of Neuroscience, 1997, 17, 8187-8193.	1.7	101
411	Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006437-a006437.	2.9	101
412	Alzheimerâ€™s disease tau is a prominent pathology in LRRK2 Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 183.	2.4	101
413	Rapid and Intermittent Cotransport of Slow Component-b Proteins. Journal of Neuroscience, 2007, 27, 3131-3138.	1.7	100
414	Comparison of Cerebrospinal Fluid Levels of Tau and AÎ² 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. Archives of Neurology, 2012, 69, 1018-25.	4.9	100

#	Article	IF	Citations
415	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99
416	Cerebral ischemia and CNS transplantation. NeuroReport, 1998, 9, 3703-3709.	0.6	98
417	A â€œTwo-hitâ€•Hypothesis for Inclusion Formation by Carboxyl-terminal Fragments of TDP-43 Protein Linked to RNA Depletion and Impaired Microtubule-dependent Transport. Journal of Biological Chemistry, 2011, 286, 18845-18855.	1.6	98
418	Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 7392-7402.	1.7	98
419	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	0.9	98
420	Primitive Neuroectodermal Tumors of the Central Nervous System. Brain Pathology, 1997, 7, 765-784.	2.1	97
421	Frontotemporal dementia with novel tau pathology and a Glu342Valtau mutation. Annals of Neurology, 2000, 48, 850-858.	2.8	97
422	High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochemical and Biophysical Research Communications, 2007, 358, 1-6.	1.0	97
423	Saccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease. Archives of Neurology, 2012, 69, 509.	4.9	97
424	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
425	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
426	Expression oftrk receptors in the developing and adult human central and peripheral nervous system. Journal of Comparative Neurology, 1995, 356, 387-397.	0.9	96
427	Epitope mapping of LB509, a monoclonal antibody directed against human Î±-synuclein. Neuroscience Letters, 1999, 269, 13-16.	1.0	96
428	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	1.7	96
429	Cerebrospinal fluid tau, AÎ², and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.4	96
430	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, 2010, 31, 1340-1354.	1.5	95
431	Intraneuronal APP, Not Free AÎ² Peptides in 3xTg-AD Mice: Implications for Tau versus AÎ²-Mediated Alzheimer Neurodegeneration. Journal of Neuroscience, 2011, 31, 7691-7699.	1.7	95
432	TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathologica, 2013, 125, 121-131.	3.9	95

#	Article	IF	Citations
433	A90V TDPâ€43 variant results in the aberrant localization of TDPâ€43 in vitro. FEBS Letters, 2008, 582, 2252-2256.	1.3	94
434	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-Î²42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. Journal of Alzheimer's Disease, 2014, 41, 441-451.	1.2	94
435	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	4.9	94
436	Medial pulvinar afferents to frontal eye fields in rhesus monkey demonstrated by horseradish peroxidase. Brain Research, 1974, 80, 395-411.	1.1	93
437	Molecular milestones that signal axonal maturation and the commitment of human spinal cord precursor cells to the neuronal or glial phenotype in development. Journal of Comparative Neurology, 1991, 310, 285-299.	0.9	93
438	Effects of Î±-tocopherol on an animal model of tauopathies. Free Radical Biology and Medicine, 2004, 37, 176-186.	1.3	92
439	Neuropathologic, Biochemical, and Molecular Characterization of the Frontotemporal Dementias. Journal of Neuropathology and Experimental Neurology, 2005, 64, 420-428.	0.9	92
440	Interactions of Amyloidogenic Proteins. NeuroMolecular Medicine, 2003, 4, 49-58.	1.8	91
441	Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. Journal of Comparative Neurology, 2003, 456, 176-183.	0.9	91
442	Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1601.	4.9	91
443	Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer's and Dementia, 2016, 12, 1051-1065.	0.4	91
444	Cell-to-Cell Transmission of Tau and Î±-Synuclein. Trends in Molecular Medicine, 2020, 26, 936-952.	3.5	91
445	Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. Archives of Neurology, 2010, 67, 1238-50.	4.9	90
446	CSF Î±-synuclein improves diagnostic and prognostic performance of CSF tau and AÎ² in Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 126, 683-697.	3.9	90
447	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	1.7	90
448	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
449	Longitudinal analyses of cerebrospinal fluid Î±â€Synuclein in prodromal and early Parkinson's disease. Movement Disorders, 2019, 34, 1354-1364.	2.2	89
450	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological Î±-Synuclein Insult. Neuron, 2020, 105, 822-836.e7.	3.8	89

#	Article	IF	Citations
451	Validation of Plasma Amyloid-Î² 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.5	89
452	Amygdaloid projections to prefrontal granular cortex in rhesus monkey demonstrated with horseradish peroxidase. Brain Research, 1975, 100, 132-139.	1.1	88
453	Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Research, 1993, 618, 333-337.	1.1	88
454	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp>C9ORF</scp>72â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	2.8	88
455	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	2.8	88
456	Nosology of Parkinsonâ€™s Disease: Looking for the Way Out of a Quackmire. Neuron, 2005, 47, 479-482.	3.8	87
457	Characterization of AÎ²11-40/42 peptide deposition in Alzheimerâ€™s disease and young Downâ€™s syndrome brains: implication of N-terminally truncated AÎ² species in the pathogenesis of Alzheimerâ€™s disease. Acta Neuropathologica, 2006, 112, 163-174.	3.9	87
458	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorganic and Medicinal Chemistry, 2014, 22, 5040-5049.	1.4	87
459	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
460	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
461	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene, 2000, 19, 2043-2051.	2.6	86
462	Conversion between Miniâ€Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scaleâ€2 scores in Parkinson's disease. Movement Disorders, 2014, 29, 1809-1815.	2.2	86
463	Genetically Modified NT2N Human Neuronal Cells Mediate Long-Term Gene Expression as CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental Traumatic Brain Injury. Journal of Neuropathology and Experimental Neurology, 2003, 62, 368-380.	0.9	84
464	Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders. Neurochemical Research, 2004, 29, 1053-1064.	1.6	84
465	Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimerâ€™s Disease and Related Tauopathies. Journal of Medicinal Chemistry, 2014, 57, 6116-6127.	2.9	84
466	Human fetal hippocampal development: II. The neuronal cytoskeleton. , 1996, 367, 293-307.		83
467	Internexin, MAP1B, and nestin in cortical dysplasia as markers of developmental maturity. Acta Neuropathologica, 1997, 93, 619-627.	3.9	83
468	Twofold overexpression of human ?-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. , 1998, 392, 428-438.		83

#	Article	IF	Citations
469	Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. Archives of Neurology, 2009, 66, 1359-64.	4.9	83
470	Ex VivoGene Therapy Using Targeted Engraftment of NGF-Expressing Human NT2N Neurons Attenuates Cognitive Deficits Following Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2004, 21, 1723-1736.	1.7	82
471	Neocortical and hippocampal amyloid-Î² and tau measures associate with dementia in the oldest-old. Brain, 2011, 134, 3708-3715.	3.7	82
472	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 949-955.	0.9	82
473	Multisite assessment of NIAâ€AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 164-169.	0.4	82
474	The Fluorescent Congo Red Derivative, (Trans,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 552 Td (Trans)â^'1-Bromo-2,5-Bis-(3-Hydroxycarbon Sheet Structures in Postmortem Human Neurodegenerative Disease Brains. American Journal of Pathology, 2001, 159, 937-943.	1.9	81
475	Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 935-937.	3.9	81
476	Expression of neuronal and glial polypeptides during histogenesis of the human cerebellar cortex including observations on the dentate nucleus. Journal of Comparative Neurology, 1993, 334, 356-369.	0.9	80
477	D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathologica, 2005, 109, 497-502.	3.9	80
478	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain, 2019, 142, 3565-3579.	3.7	80
479	Biomarker discovery for Alzheimerâ€™s disease, frontotemporal lobar degeneration, and Parkinsonâ€™s disease. Acta Neuropathologica, 2010, 120, 385-399.	3.9	79
480	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Frontiers in Aging Neuroscience, 2013, 5, 6.	1.7	79
481	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
482	Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathologica, 2007, 115, 123-131.	3.9	78
483	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. Journal of Histochemistry and Cytochemistry, 2000, 48, 1627-1637.	1.3	77
484	Pathological tau: a loss of normal function or a gain in toxicity?. Nature Neuroscience, 2005, 8, 1136-1137.	7.1	77
485	Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. Brain and Language, 2013, 127, 106-120.	0.8	77
486	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications, 2014, 2, 26.	2.4	77

#	Article	IF	Citations
487	Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathologica Communications, 2018, 6, 50.	2.4	77
488	Neuronal Origin of Human Esthesioneuroblastoma Demonstrated with Anti-Neurofilament Monoclonal Antibodies. New England Journal of Medicine, 1982, 307, 159-161.	13.9	76
489	Long-term integration and neuronal differentiation of human embryonal carcinoma cells (NT era-2) transplanted into the caudoputamen of nude mice. , 1996, 376, 603-613.		76
490	Update on the Neuropathological Diagnosis of Frontotemporal Dementias. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1123-1126.	0.9	76
491	Expression of ?-, ?-, and ?-synuclein in glial tumors and medulloblastomas. Acta Neuropathologica, 2003, 106, 167-175.	3.9	76
492	Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density. American Journal of Pathology, 2003, 163, 1615-1621.	1.9	76
493	Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. Acta Neuropathologica, 2011, 122, 715-726.	3.9	76
494	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Movement Disorders, 2014, 29, 1258-1264.	2.2	76
495	Î±-Synuclein (Î±Syn) Preformed Fibrils Induce Endogenous Î±Syn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons. Journal of Neuroscience, 2019, 39, 5080-5094.	1.7	76
496	The development and convergence of co-pathologies in Alzheimerâ€™s disease. Brain, 2021, 144, 953-962.	3.7	76
497	Characterization of unmyelinated axons uniting epidermal and dermal immune cells in primate and murine skin. Journal of Cutaneous Pathology, 1998, 25, 20-29.	0.7	75
498	Reduction of Detyrosinated Microtubules and Golgi Fragmentation Are Linked to Tau-Induced Degeneration in Astrocytes. Journal of Neuroscience, 2003, 23, 10662-10671.	1.7	75
499	Î²-synuclein modulates Î±-synuclein neurotoxicity by reducing Î±-synuclein protein expression. Human Molecular Genetics, 2006, 15, 3002-3011.	1.4	75
500	Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron, 2016, 91, 41-55.	3.8	75
501	Impaired Rapid Eye Movement Sleep in the Tg2576 APP Murine Model of Alzheimer's Disease with Injury to Pedunculopontine Cholinergic Neurons. American Journal of Pathology, 2005, 167, 1361-1369.	1.9	74
502	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 442.	4.5	74
503	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiology of Disease, 2017, 105, 328-335.	2.1	74
504	Transmission of Î±-synuclein seeds in neurodegenerative disease: recent developments. Laboratory Investigation, 2019, 99, 971-981.	1.7	74

#	Article	IF	Citations
505	A combined horseradish peroxidase-autoradiographic investigation of reciprocal connections between superior temporal gyrus and pulvinar in squirrel monkey. Brain Research, 1975, 85, 347-353.	1.1	73
506	PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats. PLoS ONE, 2011, 6, e17951.	1.1	73
507	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimerâ€™s disease, and Parkinsonâ€™s disease. Journal of Neurology, 2018, 265, 1365-1375.	1.8	73
508	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
509	Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. Journal of Experimental Medicine, 2020, 217, .	4.2	73
510	Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts. Journal of Neuropathology and Experimental Neurology, 1989, 48, 48-68.	0.9	72
511	Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats. Journal of Neurosurgery, 1999, 90, 116-124.	0.9	72
512	T1Ï•MRI of Alzheimer's disease. NeuroImage, 2008, 41, 1199-1205.	2.1	72
513	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
514	Quantification of Modified Amyloid Î² Peptides in Alzheimer Disease and Down Syndrome Brains. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1089-1095.	0.9	71
515	Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments. Journal of Neuroscience, 2001, 21, 6026-6035.	1.7	71
516	Biochemical Analysis of Ï„ Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease. American Journal of Pathology, 2002, 161, 1135-1141.	1.9	71
517	17q-Linked Frontotemporal Dementiaâ€“Amyotrophic Lateral Sclerosis Without Tau Mutations With Tau and Î±-Synuclein Inclusions. Archives of Neurology, 2004, 61, 398.	4.9	71
518	The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology, 2015, 84, 927-934.	1.5	71
519	Neurofibrillary Tangles in Progressive Supranuclear Palsy Contain the Same Tau Epitopes Identified in AlzheimerÊ¼s Disease PHFtau. Journal of Neuropathology and Experimental Neurology, 1996, 55, 534-539.	0.9	70
520	Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. Annals of Neurology, 1996, 39, 481-489.	2.8	70
521	Quantitative neurohistological features of frontotemporal degeneration. Neurobiology of Aging, 2000, 21, 913-919.	1.5	70
522	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70

#	Article	IF	Citations
523	Cellular and Molecular Neuropathology of the Olfactory Epithelium and Central Olfactory Pathways in Alzheimer's Disease and Schizophreniaa. Annals of the New York Academy of Sciences, 1998, 855, 762-775.	1.8	69
524	Ï„ Phosphorylation in Human, Primate, and Rat Brain: Evidence that a Pool of Ï„ Is Highly Phosphorylated In Vivo and Is Rapidly Dephosphorylated In Vitro. Journal of Neurochemistry, 1994, 63, 2279-2287.	2.1	69
525	A Review and Rationale for the Use of Cellular Transplantation as a Therapeutic Strategy for Traumatic Brain Injury. Journal of Neurotrauma, 2004, 21, 1501-1538.	1.7	69
526	Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum. Archives of Neurology, 2010, 67, 688.	4.9	69
527	Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. Journal of Neuropathology and Experimental Neurology, 2018, 77, 216-228.	0.9	69
528	Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathology, 2017, 27, 675-690.	2.1	68
529	CSF tau and Î²-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.5	68
530	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimerâ€™s disease patient brain samples. Acta Neuropathologica, 2019, 138, 613-630.	3.9	68
531	Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. Journal of Comparative Neurology, 1993, 329, 328-336.	0.9	67
532	Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic Acid. Journal of Neuroscience, 2003, 23, 8872-8880.	1.7	67
533	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	1.2	67
534	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Scientific Reports, 2016, 6, 34904.	1.6	67
535	Selective Degeneration of Purkinje Cells with Lewy Body-Like Inclusions in Aged NFHLACZ Transgenic Mice. Journal of Neuroscience, 1997, 17, 1064-1074.	1.7	66
536	Long-term deep brain stimulation in a patient with essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral thalamus. Journal of Neurosurgery, 2000, 93, 140-144.	0.9	66
537	Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB Journal, 2004, 18, 1129-1131.	0.2	66
538	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	3.9	65
539	Sex differences in the genetic predictors of Alzheimerâ€™s pathology. Brain, 2019, 142, 2581-2589.	3.7	65
540	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 119, 111-122.	3.9	64

#	Article	IF	Citations
541	Astrocytic TDP-43 Pathology in Alexander Disease. Journal of Neuroscience, 2014, 34, 6448-6458.	1.7	64
542	Cognitive profile of LRRK2â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	2.2	64
543	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
544	Peroxidase labeled subcortical afferents to pulvinar in rhesus monkey. Brain Research, 1975, 97, 144-150.	1.1	63
545	Parkinsonâ€™s Disease and Related Synucleinopathies are a New Class of Nervous System Amyloidoses. NeuroToxicology, 2002, 23, 457-460.	1.4	63
546	Building an integrated neurodegenerative disease database at an academic health center. Alzheimer's and Dementia, 2011, 7, e84-93.	0.4	63
547	TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Current Biology, 2017, 27, 3579-3590.e6.	1.8	63
548	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Movement Disorders, 2021, 36, 2945-2950.	2.2	63
549	A frontal variant of Alzheimerâ€™s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochemistry International, 2000, 37, 17-31.	1.9	62
550	The role of tau in Alzheimer's disease. Medical Clinics of North America, 2002, 86, 615-627.	1.1	62
551	Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy. Journal of Neuroscience, 2016, 36, 7707-7717.	1.7	62
552	TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. Archives of Neurology, 2007, 64, 1449.	4.9	61
553	Transactive Response DNA-Binding Protein 43 Burden in Familial Alzheimer Disease and Down Syndrome. Archives of Neurology, 2009, 66, 1483-8.	4.9	61
554	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiology of Aging, 2018, 63, 75-87.	1.5	61
555	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	3.9	60
556	Genome-wide, high-content siRNA screening identifies the Alzheimerâ€™s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathologica, 2017, 133, 955-966.	3.9	60
557	Comparison of xMAP and ELISA Assays for Detecting Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 439-445.	1.2	59
558	TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathologica, 2008, 115, 305-311.	3.9	58

#	Article	IF	Citations
559	Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimers Disease and Related Tauopathies. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 432-450.	1.3	58
560	Olfactory dysfunction occurs in transgenic mice overexpressing human Ï„ protein. Brain Research, 2004, 1000, 174-178.	1.1	57
561	Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression. Cell Reports, 2020, 33, 108398.	2.9	57
562	Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiology of Aging, 1994, 15, 299-303.	1.5	56
563	Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. Annals of Clinical and Translational Neurology, 2016, 3, 399-403.	1.7	56
564	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain, 2018, 141, 288-301.	3.7	56
565	An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nature Communications, 2020, 11, 5522.	5.8	56
566	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
567	Cerebellar Dysplasias in Humans: Development and Possible Relationship to Glial and Primitive Neuroectodermal Tumors of the Cerebellar Vermis. Journal of Neuropathology and Experimental Neurology, 1994, 53, 61-71.	0.9	55
568	Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. Annals of Neurology, 1998, 43, 259-265.	2.8	55
569	Microtubule-stabilising drugs for therapy of Alzheimerâ€™s disease and other neurodegenerative disorders with axonal transport impairments. Expert Opinion on Pharmacotherapy, 2005, 6, 683-686.	0.9	55
570	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 9-12.	0.3	55
571	Patterns of Striatal Degeneration in Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2013, 27, 74-83.	0.6	55
572	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Annals of Neurology, 2020, 88, 574-587.	2.8	55
573	AD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Science Translational Medicine, 2021, 13, eabe3947.	5.8	55
574	A68 is a component of paired helical filaments of Gerstmann-StrÃussler-Scheinker disease, Indiana kindred. Brain Research, 1993, 616, 325-329.	1.1	54
575	Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet, The, 1998, 351, 884.	6.3	54
576	A Novel Apoptotic Pathway Induced by Nerve Growth Factor-mediated TrkA Activation in Medulloblastoma. Journal of Biological Chemistry, 2000, 275, 565-570.	1.6	54

#	Article	IF	Citations
577	Tauists, Baptists, Syners, Apostates, and new data. Annals of Neurology, 2002, 52, 263-265.	2.8	54
578	Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. Journal of Alzheimer's Disease, 2006, 9, 257-262.	1.2	54
579	Cytoskeletal Requirements in Axonal Transport of Slow Component-b. Journal of Neuroscience, 2008, 28, 5248-5256.	1.7	54
580	Longitudinal plasma amyloid beta as a biomarker of Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 843-850.	1.4	54
581	Building a roadmap for developing combination therapies for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 327-333.	1.4	54
582	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	1.2	54
583	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	4.5	54
584	Terminally Differentiated Human Neurons Survive and Integrate Following Transplantation into the Traumatically Injured Rat Brain. Journal of Neurotrauma, 1999, 16, 403-414.	1.7	53
585	Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Journal of Neurosurgery, 2004, 100, 553-556.	0.9	53
586	Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. Acta Neuropathologica, 2007, 113, 543-548.	3.9	53
587	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiology of Aging, 2010, 31, 1386-1400.	1.5	53
588	T1rho (T1Ï) MR imaging in Alzheimerâ€™ disease and Parkinsonâ€™s disease with and without dementia. Journal of Neurology, 2011, 258, 380-385.	1.8	53
589	Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. Lecture Notes in Computer Science, 2011, 7012, 27-34.	1.0	53
590	The older rabbit as an animal model: Implications for Alzheimer's disease. Neurobiology of Aging, 1996, 17, 283-290.	1.5	52
591	Neural differentiation of rhesus embryonic stem cells. Apmis, 1998, 106, 149-157.	0.9	52
592	Accumulation of Intracellular Amyloid-Î² Peptide (AÎ² 1â€“40) in Mucopolysaccharidosis Brains. Journal of Neuropathology and Experimental Neurology, 1999, 58, 815-824.	0.9	52
593	Clinical, Genetic, and Pathologic Characteristics of Patients With Frontotemporal Dementia and Progranulin Mutations. Archives of Neurology, 2007, 64, 1148.	4.9	52
594	Amyotrophic Lateral Sclerosisâ€“Plus Syndrome With TAR DNA-Binding Protein-43 Pathology. Archives of Neurology, 2009, 66, 121-4.	4.9	52

#	Article	IF	Citations
595	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathologica, 2011, 121, 509-517.	3.9	52
596	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	1.5	52
597	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	2.8	52
598	Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue. Nature Biotechnology, 2022, 40, 1082-1092.	9.4	52
599	Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathologica, 2003, 105, 469-476.	3.9	51
600	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
601	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.4	51
602	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	2.8	51
603	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
604	A light and electron microscopic study of the intraneuronal transport of horseradish peroxidase and wheat germ agglutinin-peroxidase conjugates in the rat visual system. Journal of Neurocytology, 1981, 10, 441-456.	1.6	50
605	Distribution of phosphate-independent MAP2 epitopes revealed with monoclonal antibodies in microwave-denatured human nervous system tissues. Journal of Neuroscience Methods, 1989, 29, 171-180.	1.3	50
606	An extensive network of PHFÏ„-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Letters, 1994, 344, 69-73.	1.3	50
607	Î²-Amyloid Peptide and Amyloid Precursor Proteins in Olfactory Mucosa of Patients with Alzheimer's Disease, Parkinson's Disease, and down Syndrome. Annals of Otology, Rhinology and Laryngology, 1995, 104, 655-661.	0.6	50
608	?-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathologica, 2004, 108, 213-23.	3.9	50
609	Derivation of cutoffs for the Elecsys^{Â®} amyloid Î² (1â€“42) assay in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 698-705.	1.2	50
610	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathologica, 2019, 138, 795-811.	3.9	50
611	Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimerâ€™s disease. Brain, 2020, 143, 1572-1587.	3.7	50
612	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. PLoS ONE, 2013, 8, e70269.	1.1	50

#	Article	IF	Citations
613	Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. Brain Research, 1992, 585, 386-390.	1.1	49
614	Isomerization of (Z,Z) to (E,E)1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in Strong Base:Â Probes for Amyloid Plaques in the Brain. Journal of Medicinal Chemistry, 2001, 44, 2270-2275.	2.9	49
615	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of AÎ²42 and Its Protein Aggregates. Molecular Neurobiology, 2020, 57, 3803-3813.	1.9	49
616	Î±-Synuclein modulates tau spreading in mouse brains. Journal of Experimental Medicine, 2021, 218, .	4.2	49
617	Monoclonal antibodies to purified cortical lewy bodies recognize the mid-size neurofilament subunit. Annals of Neurology, 1997, 42, 595-603.	2.8	48
618	[6] Purification of paired helical filament tau and normal tau from human brain tissue. Methods in Enzymology, 1999, 309, 81-89.	0.4	48
619	The power of neuroimaging biomarkers for screening frontotemporal dementia. Human Brain Mapping, 2014, 35, 4827-4840.	1.9	48
620	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.5	48
621	Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2017, 13, 106-115.	1.4	48
622	Primum non nocere: a call for balance when reporting on CTE. Lancet Neurology, The, 2019, 18, 231-233.	4.9	48
623	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
624	Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. Molecular and Chemical Neuropathology, 1992, 17, 121-135.	1.0	47
625	Animal Models of Medulloblastomas and Related Primitive Neuroectodermal Tumors. A Review. Journal of Neuropathology and Experimental Neurology, 1995, 54, 285-296.	0.9	47
626	Delayed Transplantation of Human Neurons following Brain Injury in Rats: A Long-Term Graft Survival and Behavior Study. Journal of Neurotrauma, 2005, 22, 1456-1474.	1.7	47
627	Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Letters, 2005, 579, 2564-2568.	1.3	47
628	Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation. Journal of Medicinal Chemistry, 2010, 53, 3739-3747.	2.9	47
629	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	0.9	47
630	Measurements of autoâ€antibodies to Î±â€synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. Journal of Neurochemistry, 2018, 145, 489-503.	2.1	47

#	Article	IF	Citations
631	Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. Annals of Neurology, 1999, 46, 271-273.	2.8	46
632	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. Journal of Chemical Neuroanatomy, 2000, 20, 225-244.	1.0	46
633	Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (Î±-Syn) Pathology in Synthetic Î±-Syn Fibril-Induced Mouse Models of Synucleinopathy. Journal of Neuropathology and Experimental Neurology, 2019, 78, 877-890.	0.9	46
634	Expression of neurofilament and neuron-specific enolase in small cell tumors of skin using immunohistochemistry. Cancer, 1985, 56, 625-631.	2.0	45
635	Increased Vulnerability of NFH-LacZ Transgenic Mouse to Traumatic Brain Injury-Induced Behavioral Deficits and Cortical Damage. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 762-770.	2.4	45
636	The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 372-378.	0.9	45
637	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage: Clinical, 2014, 4, 461-472.	1.4	45
638	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathologica Communications, 2016, 4, 106.	2.4	45
639	Malignant pineocytoma with prominent papillary features. Cancer, 1982, 50, 1789-1793.	2.0	44
640	A quantitative correlation of substance P-, calcitonin gene-related peptide- and cholecystokinin-like immunoreactivity with retrogradely labeled trigeminal ganglion cells innervating the eye. Brain Research, 1987, 405, 220-226.	1.1	44
641	Therapy of a Murine Model of Pediatric Brain Tumors using a Herpes Simplex Virus Type-1 ICP34.5 Mutant and Demonstration of Viral Replication within the CNS. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1259-1269.	0.9	44
642	Cognitive Impairment in Elderly Schizophrenia: A Dementia (Still) Lacking Distinctive Histopathology. Schizophrenia Bulletin, 1996, 22, 5-9.	2.3	44
643	Spinal Cord Neurofibrillary Pathology in Alzheimer Disease and Guam Parkinsonism-Dementia Complex. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1075-1086.	0.9	44
644	Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias^a. Annals of the New York Academy of Sciences, 1994, 747, 92-109.	1.8	44
645	Progression of alphaâ€synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathology and Applied Neurobiology, 2017, 43, 315-329.	1.8	44
646	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	3.7	44
647	Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI Data. Journal of Alzheimer's Disease, 2011, 26, 77-90.	1.2	43
648	Association of plasma and cortical amyloid beta is modulated by APOE Îµ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.4	43

#	Article	IF	Citations
649	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiology of Aging, 2014, 35, 1473-1482.	1.5	43
650	Semi-Automated Digital Image Analysis of Pickâ€™s Disease and TDP-43 Proteinopathy. Journal of Histochemistry and Cytochemistry, 2016, 64, 54-66.	1.3	43
651	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 843-852.	0.4	43
652	A Review and Rationale for the Use of Genetically Engineered Animals in the Study of Traumatic Brain Injury. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1241-1258.	2.4	42
653	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging, 2014, 35, 614-622.	1.5	42
654	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.5	42
655	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 21-26.	1.1	42
656	Characterization of Parkinsonâ€™s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Medicine, 2019, 16, e1002931.	3.9	42
657	Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes. Brain Research, 1991, 556, 181-195.	1.1	41
658	Detection of Amyloid Plaques by Radioligands for Aî²40 and Aî²42: Potential Imaging Agents in Alzheimer's Patients. Journal of Molecular Neuroscience, 2003, 20, 15-24.	1.1	41
659	FGF20 and Parkinson's disease: No evidence of association or pathogenicity via î±â€synuclein expression. Movement Disorders, 2009, 24, 455-459.	2.2	41
660	Behavioral Variant Frontotemporal Dementia with Corticobasal Degeneration Pathology: Phenotypic Comparison to bvFTD with Pickâ€™s Disease. Journal of Molecular Neuroscience, 2011, 45, 594-608.	1.1	41
661	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. PLoS ONE, 2013, 8, e55531.	1.1	41
662	Validation of the Erlangen Score Algorithm for the Prediction of the Development ofÂDementia due to Alzheimerâ€™s Disease inÂPre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	1.2	41
663	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
664	Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 99-107.	1.2	41
665	Plasma <scp>EGF</scp> and cognitive decline in Parkinson's disease and Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 346-355.	1.7	41
666	Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor. Brain Communications, 2021, 3, fcab011.	1.5	41

#	Article	IF	Citations
667	Cognitive reserve in frontotemporal degeneration. Neurology, 2016, 87, 1813-1819.	1.5	40
668	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimerâ€™s and Other Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2017, 60, 5120-5145.	2.9	40
669	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017, 4, 15-25.	1.7	40
670	Divergent patterns of TDPâ€43 and tau pathologies in primary progressive aphasia. Annals of Neurology, 2019, 85, 630-643.	2.8	40
671	Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin. PLoS ONE, 2015, 10, e0141836.	1.1	40
672	Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochemical Society Transactions, 2012, 40, 661-666.	1.6	39
673	An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Human Molecular Genetics, 2015, 24, 7241-7254.	1.4	39
674	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
675	LRRK2 inhibition does not impart protection from Î±-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathologica Communications, 2019, 7, 28.	2.4	39
676	Expression of Neurofilament Antigens by Normal and Neoplastic Human Adrenal Chromaffin Cells. New England Journal of Medicine, 1985, 313, 101-104.	13.9	38
677	High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nature Biotechnology, 1999, 17, 53-57.	9.4	38
678	Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Annals of Neurology, 2006, 60, 335-345.	2.8	38
679	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	0.9	38
680	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
681	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. Brain, 2021, 144, 2784-2797.	3.7	38
682	Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1. Journal of Neuroscience, 1996, 16, 5644-5653.	1.7	37
683	Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathologica, 2012, 124, 221-230.	3.9	37
684	The transitional association between Î²â€amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.4	37

#	Article	IF	Citations
685	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. Movement Disorders, 2015, 30, 805-812.	2.2	37
686	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2017, 56, 211.e1-211.e7.	1.5	37
687	Longitudinal progression of grey matter atrophy in non-amnestic Alzheimerâ€™s disease. Brain, 2019, 142, 1701-1722.	3.7	37
688	Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathologica, 2020, 140, 831-849.	3.9	37
689	Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT). , 1999, 415, 404-418.		36
690	Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam. Experimental Neurology, 2002, 176, 1-11.	2.0	36
691	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathologica, 2003, 106, 243-250.	3.9	36
692	Characterization of tau binding by gosuranemab. Neurobiology of Disease, 2020, 146, 105120.	2.1	36
693	Overview of Protein Aggregation in Single, Double, and Triple Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 1-6.	1.8	35
694	Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to the Design of Potent Thromboxane (A2) Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 6969-6983.	2.9	35
695	APOE, thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	2.2	35
696	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
697	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	0.9	35
698	Expression of Neurofilament Proteins in the Hypertrophic Granule Cells of Lhermitte-Duclos Disease: An Explanation for the Mass Effect and the Myelination of Parallel Fibers in the Disease State. Journal of Neuropathology and Experimental Neurology, 1988, 47, 206-216.	0.9	34
699	Apolipoprotein E genotype in schizophrenia. NeuroReport, 1997, 8, 1523-1526.	0.6	34
700	CSF betaâ€amyloid 1â€“42 â€“ what are we measuring in Alzheimer's disease?. Annals of Clinical and Translational Neurology, 2015, 2, 131-139.	1.7	34
701	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2017, 5, 68.	2.4	34
702	Cerebrospinal fluid Î±â€synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1052-1062.	0.4	34

#	Article	IF	Citations
703	LRRK2 activity does not dramatically alter Î±-synuclein pathology in primary neurons. Acta Neuropathologica Communications, 2018, 6, 45.	2.4	34
704	<scp>Î±</scp>â€Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in <scp>BACâ€‹SNCA</scp> Mice. Movement Disorders, 2021, 36, 2036-2047.	2.2	34
705	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
706	Asymmetric bilateral demyelinating optic neuropathy from tacrolimus toxicity. Journal of the Neurological Sciences, 2011, 301, 112-115.	0.3	33
707	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. ACS Medicinal Chemistry Letters, 2013, 4, 886-889.	1.3	33
708	Regional brain amyloid-Î² accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	1.1	33
709	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33
710	Endoscopic Human Olfactory Biopsy Technique. Laryngoscope, 1993, 103, 815???819.	1.1	32
711	Frontotemporal dementia and tauopathy. Current Neurology and Neuroscience Reports, 2001, 1, 413-421.	2.0	32
712	Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment. Archives of Neurology, 2011, 68, 113.	4.9	32
713	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathologica Communications, 2013, 1, 36.	2.4	32
714	Neuropathology and <scp>C</scp>ellular <scp>P</scp>athogenesis of <scp>S</scp>pinocerebellar <scp>A</scp>taxia <scp>T</scp>ype 12. Movement Disorders, 2015, 30, 1813-1824.	2.2	32
715	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. ACS Medicinal Chemistry Letters, 2017, 8, 864-868.	1.3	32
716	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
717	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathologica Communications, 2021, 9, 134.	2.4	32
718	Development and in vitro Characterization of a Cationized Monoclonal Antibody against Î²A4 Protein: A Potential Probe for Alzheimer's Disease. Bioconjugate Chemistry, 1994, 5, 119-125.	1.8	31
719	Transgenic Models of Tauopathies and Synucleinopathies. Brain Pathology, 1999, 9, 733-739.	2.1	31
720	Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: Implications for improving therapy of spinal cord injury. Progress in Brain Research, 2000, 128, 299-307.	0.9	31

#	Article	IF	Citations
721	Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimerâ€™s disease. Journal of Molecular Neuroscience, 2002, 19, 7-10.	1.1	31
722	Use of Alzheimer Disease Biomarkers. JAMA - Journal of the American Medical Association, 2009, 302, 436.	3.8	31
723	Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4980-4982.	1.0	31
724	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2019, 73, 190-199.	1.5	31
725	Characterization of hippocampal subfields using ex vivo MRI and histology data: Lessons for in vivo segmentation. Hippocampus, 2020, 30, 545-564.	0.9	31
726	Characterization of novel conformation-selective Î±-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Neurobiology of Disease, 2020, 136, 104712.	2.1	31
727	Association of CSF AÎ², amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology, 2020, 95, e2075-e2085.	1.5	31
728	Normalization of CSF pTau measurement by AÎ²40 improves its performance as a biomarker of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 97.	3.0	31
729	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625.	2.2	31
730	A morphometric study of the endocytosis of wheat germ agglutinin-horseradish peroxidase conjugates by retinal ganglion cells in the rat. Brain Research, 1983, 272, 201-210.	1.1	30
731	Rational design of an animal model for alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. Neurobiology of Aging, 1996, 17, 173-182.	1.5	30
732	A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurocase, 2009, 15, 235-247.	0.2	30
733	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiology of Aging, 2015, 36, 273-282.	1.5	30
734	Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. Journal of Neuroscience, 2017, 37, 5870-5884.	1.7	30
735	The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0193707.	1.1	30
736	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. Science Translational Medicine, 2019, 11, .	5.8	30
737	In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. Acta Neuropathologica, 2021, 141, 193-215.	3.9	30
738	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	2.8	30

#	Article	IF	Citations
739	Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. Science Advances, 2021, 7, .	4.7	30
740	Toxicity and Neuronal Infection of a HSV-1 ICP34.5 Mutant in Nude Mice. Journal of NeuroVirology, 1998, 4, 100-105.	1.0	29
741	Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathologica, 2003, 105, 177-184.	3.9	29
742	New directions for frontotemporal dementia drug discovery. , 2008, 4, 89-93.		29
743	Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structureâ€“activity relationship leads to selection of candidates with desirable in vivo properties. Bioorganic and Medicinal Chemistry, 2012, 20, 4451-4461.	1.4	29
744	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. Dementia and Geriatric Cognitive Disorders, 2015, 39, 154-166.	0.7	29
745	T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. NeuroImage: Clinical, 2015, 7, 598-604.	1.4	29
746	Caregiver report of apathy predicts dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 992-995.	1.1	29
747	A Longitudinal Study of Total and Phosphorylated Î±-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1541-1553.	1.2	29
748	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
749	Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathologica Communications, 2021, 9, 188.	2.4	29
750	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	3.9	29
751	Neuroanatomical correlates of selective downgaze paralysis. Journal of the Neurological Sciences, 1981, 52, 91-101.	0.3	28
752	Neurofilament and chromogranin expression in normal and neoplastic neuroendocrine cells of the human gastrointestinal tract and pancreas. Cancer, 1990, 65, 1219-1227.	2.0	28
753	Co-occurrence of Parkinson's disease with progressive supranuclear palsy. Acta Neuropathologica, 2002, 103, 526-530.	3.9	28
754	Effects of Î³-Secretase Inhibition on the Amyloid Î² Isoform Pattern in a Mouse Model of Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2009, 6, 258-262.	0.8	28
755	Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALSC9orf72Expansion Cases. Journal of Neuropathology and Experimental Neurology, 2015, 74, 380-387.	0.9	28
756	Amyloidâ€Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2016, 3, 367-375.	0.8	28

#	Article	IF	Citations
757	GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. Journal of Neuroscience, 2017, 37, 11485-11494.	1.7	28
758	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
759	Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiology of Disease, 2019, 124, 133-140.	2.1	28
760	Cognitive Profile and Markers of Alzheimer Diseaseâ€“Type Pathology in Patients With Lewy Body Dementias. Neurology, 2021, 96, e1855-e1864.	1.5	28
761	Coordinate reduction in cell proliferation and cell death in mouse olfactory epithelium from birth to maturity. Brain Research, 1997, 761, 347-351.	1.1	27
762	Rotenone Neurotoxicity: A New Window on Environmental Causes of Parkinson's Disease and Related Brain Amyloidoses. Experimental Neurology, 2003, 179, 6-8.	2.0	27
763	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. Molecular Neurodegeneration, 2018, 13, 59.	4.4	27
764	Detection of Alzheimerâ€™s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). Acta Neuropathologica Communications, 2019, 7, 34.	2.4	27
765	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
766	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.4	27
767	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
768	Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. Acta Neuropathologica, 2006, 111, 401-412.	3.9	26
769	T1Ï•MRI in Alzheimer's Disease: Detection of Pathological Changes in Medial Temporal Lobe. , 2011, 21, e86-e90.		26
770	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology, 2014, 83, 502-509.	1.5	26
771	A comparison of AÎ² amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathologica, 2014, 128, 543-550.	3.9	26
772	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimer's Research and Therapy, 2014, 6, 36.	3.0	26
773	Converging Patterns of Î±-Synuclein Pathology in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1005-1016.	0.9	26
774	Cerebrospinal Fluid Total and Phosphorylated Î±-Synuclein in Patients with Creutzfeldtâ€“Jakob Disease and Synucleinopathy. Molecular Neurobiology, 2019, 56, 3476-3483.	1.9	26

#	Article	IF	Citations
775	In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood. Molecular and Chemical Neuropathology, 1994, 21, 219-239.	1.0	25
776	Neurotrophin signal transduction in medulloblastoma. Journal of Neuroscience Research, 1997, 49, 522-527.	1.3	25
777	Toxicologic and Carcinogenic Effects of the Type IV Phosphodiesterase Inhibitor RP 73401 on the Nasal Olfactory Tissue in Rats. Toxicologic Pathology, 1999, 27, 383-394.	0.9	25
778	Simultaneous HPLCâ€“MSâ€“MS quantification of 8-iso-PGF2Î± and 8,12-iso-iPF2Î± in CSF and brain tissue samples with on-line cleanup. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2209-2216.	1.2	25
779	Frequency and Clinicopathological Characteristics of Presenilin 1 Gly206Ala Mutation in Puerto Rican Hispanics with Dementia. Journal of Alzheimer's Disease, 2013, 33, 1089-1095.	1.2	25
780	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug and Alcohol Dependence, 2014, 142, 262-268.	1.6	25
781	Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. Acta Neuropathologica Communications, 2014, 2, 33.	2.4	25
782	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology, 2016, 87, 1227-1234.	1.5	25
783	Distinct brainâ€derived TDPâ€43 strains from FTLDâ€TDP subtypes induce diverse morphological TDPâ€43 aggregates and spreading patterns in vitro and in vivo. Neuropathology and Applied Neurobiology, 2021, 47, 1033-1049.	1.8	25
784	Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathologica Communications, 2021, 9, 140.	2.4	25
785	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	1.1	25
786	Antibodies to the Î²-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Letters, 1990, 264, 43-47.	1.3	24
787	Apolipoprotein E ?4 allele distribution in alcoholic dementia and in Alzheimer's disease in Japan. Annals of Neurology, 1994, 36, 797-799.	2.8	24
788	The apolipoprotein E gene in Binswanger's disease and vascular dementia. Clinical Genetics, 1996, 50, 459-461.	1.0	24
789	TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. Acta Neuropathologica, 2012, 124, 285-291.	3.9	24
790	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and theÂUniversity of Washington. Alzheimer's and Dementia, 2013, 9, 609-614.	0.4	24
791	Absence of C9ORF72 expanded or intermediate repeats in autopsyâ€confirmed Parkinson's disease. Movement Disorders, 2014, 29, 827-830.	2.2	24
792	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1141-1146.	0.9	24

#	Article	IF	Citations
793	ATN status in amnestic and non-amnestic Alzheimerâ€™s disease and frontotemporal lobar degeneration. Brain, 2020, 143, 2295-2311.	3.7	24
794	Synthesis and characterization of high affinity fluorogenic Î±-synuclein probes. Chemical Communications, 2020, 56, 3567-3570.	2.2	24
795	Human Olfactory Mucosa in Schizophrenia. Annals of Otology, Rhinology and Laryngology, 1998, 107, 349-355.	0.6	23
796	A New Consensus Report on Biomarkers for the Early Antemortem Diagnosis of Alzheimer Disease: Current Status, Relevance to Drug Discovery, and Recommendations for Future Research. Journal of Neuropathology and Experimental Neurology, 1998, 57, 643-644.	0.9	23
797	Active Cigarette Smoking inÂCognitively-Normal Elders and Probable Alzheimerâ€™s Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. Journal of Alzheimer's Disease, 2016, 54, 99-107.	1.2	23
798	Longitudinal Measurements of Glucocerebrosidase activity in Parkinsonâ€™s patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	1.7	23
799	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	1.8	23
800	Continuity of neuropil threads with tangle-bearing and tangle-free neurons in Alzheimer disease cortex. Molecular and Chemical Neuropathology, 1993, 18, 299-312.	1.0	22
801	Studies of childhood brain tumors using immunohistochemistry and microwave technology: methodological considerations. Journal of Neuroscience Methods, 1994, 55, 191-200.	1.3	22
802	Human neurons that constitutively secrete AÎ² do not induce Alzheimer's disease pathology following transplantation and long-term survival in the rodent brain. Brain Research, 1995, 671, 333-337.	1.1	22
803	Dementia. Archives of Neurology, 2008, 65, 593-5.	4.9	22
804	Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2012, 3, 928-940.	1.7	22
805	The Growth and Impact of Alzheimer Disease Centers as Measured by Social Network Analysis. JAMA Neurology, 2014, 71, 412.	4.5	22
806	Defining and predicting transdiagnostic categories of neurodegenerative disease. Nature Biomedical Engineering, 2020, 4, 787-800.	11.6	22
807	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathologica Communications, 2021, 9, 30.	2.4	22
808	Tau immunotherapy is associated with glial responses in FTLD-tau. Acta Neuropathologica, 2021, 142, 243-257.	3.9	22
809	Primitive neuroectodermal tumors of the central nervous system in childhood: tumor biological aspects. Critical Reviews in Oncology/Hematology, 1994, 17, 1-25.	2.0	21
810	Neuropsychological Subgroups in Non-Demented Parkinsonâ€™s Disease: A Latent Class Analysis. Journal of Parkinson's Disease, 2017, 7, 385-395.	1.5	21

#	Article	IF	Citations
811	Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2180-2183.	1.0	21
812	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-Î²1-42 and Hypertension. Journal of Alzheimer's Disease, 2018, 66, 1095-1104.	1.2	21
813	Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. Methods in Molecular Biology, 2019, 1948, 45-57.	0.4	21
814	PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding. Journal of Biological Chemistry, 2021, 296, 100636.	1.6	21
815	Synucleinopathies: a pathological and molecular review. Clinical Neuroscience Research, 2001, 1, 445-455.	0.8	20
816	Familial Frontotemporal Dementia: From Gene Discovery to Clinical Molecular Diagnostics. Clinical Chemistry, 2003, 49, 1717-1725.	1.5	20
817	The Alzheimer's Brain. American Journal of Pathology, 2005, 167, 1183-1188.	1.9	20
818	Increased levels of fucosyltransferase IX and carbohydrate Lewisx adhesion determinant in human NT2N neurons. Journal of Neuroscience Research, 2007, 85, 1260-1270.	1.3	20
819	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. Movement Disorders, 2016, 31, 126-134.	2.2	20
820	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
821	Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimer's and Dementia, 2017, 13, 770-777.	0.4	20
822	Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. ACS Chemical Neuroscience, 2017, 8, 5-7.	1.7	20
823	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from Î±-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
824	Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. Acta Neuropathologica Communications, 2019, 7, 65.	2.4	20
825	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Annals of Clinical and Translational Neurology, 2020, 7, 2342-2355.	1.7	20
826	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
827	Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3642-3646.	1.0	19
828	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 64.	4.4	19

#	Article	IF	Citations
829	Effects of microglial depletion and TREM2 deficiency on AÎ² plaque burden and neuritic plaque tau pathology in 5XFAD mice. Acta Neuropathologica Communications, 2021, 9, 150.	2.4	19
830	Astroglial tau pathology alone preferentially concentrates at sulcal depths in chronic traumatic encephalopathy neuropathologic change. Brain Communications, 2020, 2, fcaa210.	1.5	19
831	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
832	Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease. Journal of the American Geriatrics Society, 1997, 45, 1228-1231.	1.3	18
833	Molecular Identification of AMY, an Alzheimer Disease Amyloid-Associated Protein. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1108-1117.	0.9	18
834	Sporadic tauopathies: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease. , 2004, , 227-256.		18
835	High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. Acta Neuropathologica Communications, 2015, 3, 33.	2.4	18
836	Expression of Î²-amyloid precursor protein in the developing human spinal cord. Brain Research, 1994, 642, 132-136.	1.1	17
837	p38 Mitogen-activated Protein Kinase-independent Induction of gadd45 Expression in Nerve Growth Factor-induced Apoptosis in Medulloblastomas. Journal of Biological Chemistry, 2001, 276, 41120-41127.	1.6	17
838	Elevated YKL-40 and low sAPPÎ²:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	0.9	17
839	Evaluation of the Structureâ€“Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2021, 64, 1073-1102.	2.9	17
840	Dopamine neurons exhibit emergent glutamatergic identity in Parkinsonâ€™s disease. Brain, 2022, 145, 879-886.	3.7	17
841	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
842	Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology. NeuroImage: Clinical, 2022, 33, 102913.	1.4	17
843	Familial pineoblastoma. Journal of Neurosurgery, 1985, 62, 930-932.	0.9	16
844	Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice. Acta Neuropathologica Communications, 2016, 4, 105.	2.4	16
845	Is multiple system atrophy an infectious disease?. Annals of Neurology, 2018, 83, 10-12.	2.8	16
846	TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss. Acta Neuropathologica Communications, 2022, 10, 33.	2.4	16

#	Article	IF	Citations
847	Elevated Levels of Tau in Cerebrospinal Fluid: Implications for the Antemortem Diagnosis of Alzheimer's Disease*. Journal of Alzheimer's Disease, 1999, 1, 297-305.	1.2	15
848	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathologica, 2011, 122, 737-745.	3.9	15
849	Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults. Neurobiology of Aging, 2017, 58, 102-111.	1.5	15
850	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Movement Disorders Clinical Practice, 2019, 6, 440-445.	0.8	15
851	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	1.1	15
852	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	1.2	15
853	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer's and Dementia, 2020, 16, 1234-1247.	0.4	15
854	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. Acta Neuropathologica, 2020, 140, 675-693.	3.9	15
855	Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. Npj Vaccines, 2020, 5, 28.	2.9	15
856	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LCâ€“MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	1.5	15
857	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta Neuropathologica, 2021, 142, 629-642.	3.9	15
858	Genetic prediction of impulse control disorders in Parkinson's disease. Annals of Clinical and Translational Neurology, 2022, 9, 936-949.	1.7	15
859	Time of arrival of wheat germ agglutinin-HRP conjugates in superior colliculus after intraocular injections in the rat. Brain Research, 1983, 267, 365-370.	1.1	14
860	Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains. Annals of the New York Academy of Sciences, 1996, 786, 195-205.	1.8	14
861	Production and Characterization of Two Ependymoma Xenografts. Journal of Neuropathology and Experimental Neurology, 1996, 55, 540-548.	0.9	14
862	Brain degeneration linked to `fatal attractions'' of proteins in Alzheimer's disease and related disorders. Journal of Alzheimer's Disease, 2001, 3, 117-119.	1.2	14
863	Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His. Acta Neuropathologica Communications, 2015, 3, 42.	2.4	14
864	Role of brain infarcts in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2861-2868.	1.5	14

#	Article	IF	Citations
865	Alzheimer's genetic risk is reduced in primary ageâ€related tauopathy: a potential model of resistance?. Annals of Clinical and Translational Neurology, 2018, 5, 927-934.	1.7	14
866	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
867	Multimodal inÂvivo and postmortem assessments of tau in Lewy body disorders. Neurobiology of Aging, 2020, 96, 137-147.	1.5	14
868	Poly (ADP-ribose) Interacts With Phosphorylated Î±-Synuclein in Post Mortem PD Samples. Frontiers in Aging Neuroscience, 2021, 13, 704041.	1.7	14
869	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. Acta Neuropathologica Communications, 2021, 9, 173.	2.4	14
870	Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. Acta Neuropathologica Communications, 2013, 1, 1-11.	2.4	13
871	Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies. Korean Journal of Physiology and Pharmacology, 2014, 18, 447.	0.6	13
872	Statins and Cognition in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 661-667.	1.5	13
873	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. Frontiers in Neuroscience, 2019, 13, 682.	1.4	13
874	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 263-276.	1.2	13
875	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
876	COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI (CONNECT-TBI). Acta Neuropathologica Communications, 2021, 9, 32.	2.4	13
877	Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD. Molecular Therapy - Methods and Clinical Development, 2021, 21, 434-450.	1.8	13
878	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	3.3	13
879	Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change. Acta Neuropathologica Communications, 2022, 10, 50.	2.4	13
880	Quantitative detection of Î±-Synuclein and Tau oligomers and other aggregates by digital single particle counting. Npj Parkinson's Disease, 2022, 8, .	2.5	13
881	Enzymatic detection of native and derivatized horseradish peroxidase in sodium dodecyl sulfate polyacrylamide gels. Analytical Biochemistry, 1986, 155, 371-375.	1.1	12
882	Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual. Acta Neuropathologica, 2007, 113, 471-479.	3.9	12

#	Article	IF	Citations
883	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
884	Tauopathy with hippocampal 4â€repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathology, 2018, 28, 274-283.	2.1	12
885	Neuroimmune interactions in Alzheimer's diseaseâ€"New frontier with old challenges?. Progress in Molecular Biology and Translational Science, 2019, 168, 183-201.	0.9	12
886	Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. Journal of Alzheimer's Disease, 2020, 77, 1397-1416.	1.2	12
887	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	3.9	12
888	Selective Expression of Epitopes in Multiphosphorylation Repeats of the High and Middle Molecular Weight Neurofilament Proteins in Alzheimer Neurofibrillary Tangles. Annals of Medicine, 1989, 21, 113-116.	1.5	11
889	In situ bloodâ€"brain barrier permeability of a C-10 paclitaxel carbamate. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6119-6121.	1.0	11
890	Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497. Expert Opinion on Therapeutic Patents, 2014, 24, 355-360.	2.4	11
891	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1033-1034.	4.9	11
892	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	4.9	11
893	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	3.7	11
894	Genetic predictors of survival in behavioral variant frontotemporal degeneration. Neurology, 2019, 93, e1707-e1714.	1.5	11
895	Correction of microtubule defects within AÎ² plaqueâ€associated dystrophic axons results in lowered AÎ² release and plaque deposition. Alzheimer's and Dementia, 2020, 16, 1345-1357.	0.4	11
896	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	5.3	11
897	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. journal of applied laboratory medicine, The, 2020, 5, 183-193.	0.6	10
898	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. Journal of Biological Chemistry, 2020, 295, 4001-4013.	1.6	10
899	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
900	Disease-, region- and cell type specific diversity of Î±-synuclein carboxy terminal truncations in synucleinopathies. Acta Neuropathologica Communications, 2021, 9, 146.	2.4	10

#	Article	IF	Citations
901	Definition, clinical features and neuroanatomical basis of dementia. , 2004, , 1-33.		10
902	Regional distribution and partial molecular characterization of CD4-related mRNA in human brain and peripheral tissues. Molecular Brain Research, 1991, 10, 23-31.	2.5	9
903	The cellular and molecular biology of medulloblastoma. Current Opinion in Neurology, 1995, 8, 437-440.	1.8	9
904	TEMPORAL PROGRESSION OF HIPPOCAMPAL ATROPHY AND APOLIPOPROTEIN E GENE IN ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 1996, 44, 216-217.	1.3	9
905	Spatial Relationship of AMY Protein Deposits and Different Species of AÎ² Peptides in Amyloid Plaques of the Alzheimer Disease Brain. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1227-1233.	0.9	9
906	Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease. American Journal of Pathology, 2002, 160, 409-411.	1.9	9
907	Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4171-4175.	1.0	9
908	Hereditary tauopathies and idiopathic frontotemporal dementias. , 2004, , 257-288.		9
909	Phospholipase pathway in Alzheimer's disease brains: decrease in GÎ±i in dorsolateral prefrontal cortex. Molecular Brain Research, 1999, 66, 188-190.	2.5	8
910	PENN Neurodegenerative Disease Research â€“ In the Spirit of Benjamin Franklin. NeuroSignals, 2008, 16, 5-10.	0.5	8
911	Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects*. Journal of Forensic Sciences, 2010, 55, 642-645.	0.9	8
912	Familial and sporadic cerebral amyloid angiopathies associated with dementia and the BRI dementias. , 2004, , 330-352.		8
913	Inhibition of CK2 mitigates Alzheimerâ€™s tau pathology by preventing NR2B synaptic mislocalization. Acta Neuropathologica Communications, 2022, 10, 30.	2.4	8
914	A NovelGRNMutation (GRNc.708+6_+9delTGAG) in Frontotemporal Lobar Degeneration With TDP-43â€“Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2014, 73, 467-473.	0.9	7
915	ADNC-RS, a clinical-genetic risk score, predicts Alzheimerâ€™s pathology in autopsy-confirmed Parkinsonâ€™s disease and Dementia with Lewy bodies. Acta Neuropathologica, 2020, 140, 449-461.	3.9	7
916	Hallucinations and Development of Dementia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1643-1648.	1.5	7
917	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	4.4	7
918	Plasma <scp>MIA</scp>, <scp>CRP</scp>, and Albumin Predict Cognitive Decline in Parkinson's Disease. Annals of Neurology, 2022, 92, 255-269.	2.8	7

#	Article	IF	Citations
919	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A₂)-Receptor Antagonists. ACS Medicinal Chemistry Letters, 2014, 5, 1015-1020.	1.3	6
920	P4-076: INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF AÎ²1-42. , 2014, 10, P811-P811.		6
921	Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. Journal of Neuropathology and Experimental Neurology, 2020, 79, 941-949.	0.9	6
922	Domain structure of neurofilament subunits as revealed by monoclonal antibodies. Journal of Cellular Biochemistry, 1985, 27, 181-187.	1.2	5
923	Alzheimerâ€™s disease biomarkers: walk with deliberate haste, donâ€™t run blithely on?. Acta Neuropathologica, 2013, 126, 625-629.	3.9	5
924	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 737-745.	1.5	5
925	LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons. Journal of Parkinson's Disease, 2021, 11, 1187-1196.	1.5	5
926	Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Annals of Neurology, 2000, 48, 850-858.	2.8	5
927	Vascular dementias. , 2004, , 289-329.		5
928	Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with Î±-synuclein inclusions. , 2004, , 353-375.		5
929	Huntington's disease. , 2004, , 376-401.		5
930	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
931	Protein mis-folding emerges as a "drugable" target for discovery of novel therapies for neuropsychiatric diseases of aging. American Journal of Geriatric Psychiatry, 2004, 12, 134-5.	0.6	5
932	Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. American Journal of Geriatric Psychiatry, 2004, 12, 136-45.	0.6	5
933	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology. Neurobiology of Aging, 2022, 113, 95-107.	1.5	5
934	Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex. Acta Neuropathologica, 2020, 140, 591-593.	3.9	4
935	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	2.8	4
936	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		4

#	Article	IF	Citations
937	Hydrocephalus and dementia. , 2004, , 442-456.		4
938	Divergent Histopathological Networks of Frontotemporal Degeneration Proteinopathy Subytpes. Journal of Neuroscience, 2022, 42, 3868-3877.	1.7	4
939	Global democratic consensus on neuropathological disease criteria. Lancet Neurology, The, 2002, 1, 340.	4.9	3
940	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
941	Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2022, 10, 75.	2.4	3
942	Pathobiological features in neurodegenerative diseases: an overview. International Congress Series, 2004, 1260, 69-75.	0.2	2
943	Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease. , 2010, 2010, 241-244.		2
944	Primary or secondary prevention for AD: who cares?. Lancet Neurology, The, 2012, 11, 661-662.	4.9	2
945	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
946	Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 466-472.	1.1	2
947	[P4â€“155]: DERIVING A CUTâ€OFF FOR THE ELECSYSÂ® Î²â€AMYLOID (1â€“42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD). Alzheimer's and Dementia, 2017, 13, P1317.	0.4	2
948	Alcoholism and dementia. , 2004, , 427-441.		2
949	Living Longer and Paying the Price?. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe38-pe38.	0.9	2
950	Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau. Acta Neuropathologica Communications, 2021, 9, 184.	2.4	2
951	Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12294.	1.8	2
952	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry, 2004, 90, 1541-1541.	2.1	1
953	Animal models of neurodegenerative dementing disorders other than Alzheimer's disease. Clinical Neuroscience Research, 2004, 3, 427-427.	0.8	1
954	Frontotemporal lobar degeneration. , 2005, , 481-493.		1

#	Article	IF	Citations
955	O3-03-01: Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort. , 2010, 6, S129-S129.		1
956	O2-05-06: COMBINING CSF AB42 AND PET FLORBETAPIR TO PREDICT DIAGNOSIS, TAU, ATROPHY, AND COGNITION. , 2014, 10, P174-P174.		1
957	P1â€281: NONLINEAR Nâ€SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. Alzheimer's and Dementia, 2018, 14, P390.	0.4	1
958	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. Neurology, 2021, 96, e1755-e1760.	1.5	1
959	Neurotrophin signal transduction in medulloblastoma. Journal of Neuroscience Research, 1997, 49, 522-527.	1.3	1
960	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		1
961	Schizophrenia and its dementia. , 2004, , 497-508.		1
962	The Art and Science of Anti-Aging Therapies. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe11-pe11.	0.9	1
963	Human prion diseases. , 2004, , 402-426.		1
964	Infectious (and inflammatory) diseases causing dementia. , 2004, , 472-496.		1
965	Head injury and dementia. , 2004, , 457-471.		1
966	CSF and blood plasma mass spectrometry measures of AÎ², tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
967	Cerebrospinal fluid neurogranin in nonâ€amnestic and amnestic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
968	Calsyntenināˆ1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.4	1
969	A novel antibodyâ€free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.4	1
970	Important anatomical landmarks in the brain in dementia. , 2004, , 34-47.		0
971	Transgenic mouse models of neurodegenerative disease. , 2004, , 533-557.		0
972	S5â€02â€01: Microtubuleâ€stabilizing drugs for abrogation and prevention of Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P724.	0.4	0

#	Article	IF	Citations
973	O4â€01â€01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of AÃŸ, tau and Pâ€tau versus 83 proteomic analytes. Alzheimer's and Dementia, 2012, 8, P609.	0.4	0
974	O2-10-01: TDP-43 and mixed pathologies in normal cognition, mild cognitive impairment and dementia. , 2013, 9, P334-P334.		0
975	P3-018: INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE. , 2014, 10, P633-P633.		0
976	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
977	P4-054: ASSOCIATION OF PLASMA LEPTIN/ADIPONECTIN RATIO IN MEN WITH CSF BIOMARKERS IN THE ADNI-1 COHORT. , 2014, 10, P801-P802.		0
978	O3-12-05: INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE. , 2014, 10, P234-P234.		0
979	P2-094: COMPARING THE DIAGNOSTIC ACCURACIES OF CSF AÎ²42 AND PET FLORBETAPIR. , 2014, 10, P505-P505.		0
980	P3-017: ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE. , 2014, 10, P632-P633.		0
981	P4-377: A TOMM40 SNP IN APOE E4 NON-CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA. , 2014, 10, P926-P926.		0
982	P3-189: DIAGNOSTIC EFFECTIVENESS OF QUANTITATIVE [18F]FLUTEMETAMOL PET IMAGING IN SUBJECTS WITH NORMAL PRESSURE HYDROCEPHALUS USING BIOPSY HISTOPATHOLOGY STANDARD OF TRUTH FOR DETECTION OF FIBRILLAR AMYLOID B. , 2014, 10, P699-P699.		0
983	P4-237: WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT. , 2014, 10, P873-P874.		0
984	P1â€398: PARIETAL LOBE CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH LOWER CEREBROSPINAL FLUID BETA AMYLOID _{1â€42} IN PATIENTS WITH SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P454.	0.4	0
985	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
986	P1â€143: MULTIVARIATE GENOMEâ€WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION. Alzheimer's and Dementia, 2018, 14, P330.	0.4	0
987	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.4	0
988	P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. Alzheimer's and Dementia, 2018, 14, P275.	0.4	0
989	O2â€14â€01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. Alzheimer's and Dementia, 2018, 14, P656.	0.4	0
990	P1â€255: ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LCâ€MSâ€MS REFERENCE METHOD. Alzheimer's and Dementia, 2018, 14, P378.	0.4	0

#	Article	IF	Citations
991	P1â€419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
992	ICâ€Pâ€043: CONTRIBUTION OF TAU, TDPâ€43, Î²â€AMYLOID AND Î±â€SYNUCLEIN TO MEDIAL TEMPORAL LOBE ATROPHY. Alzheimer's and Dementia, 2019, 15, P46.	0.4	0
993	Morphometric methods and dementia. , 2004, , 75-81.		0
994	Molecular diagnosis of dementia. , 2004, , 91-112.		0
995	Neuroimaging Alzheimer's disease. , 2004, , 128-160.		0
996	Other diseases that cause dementia. , 2004, , 509-532.		0
997	Neuropathology of the ageing brain. , 2004, , 113-127.		0
998	Down's syndrome and Alzheimer's disease. , 2004, , 207-226.		0
999	Practical approach to pathological diagnosis. , 2004, , 48-74.		0
1000	Safety precautions in laboratories involved with dementia diagnosis and research. , 2004, , 82-90.		0
1001	Mechanisms of slow axonal transport of Î±â€synuclein. FASEB Journal, 2007, 21, A28.	0.2	0
1002	TDPâ€43 immunoreactivity in anoxic, ischemic and proliferating lesion of the central nervous system. FASEB Journal, 2008, 22, 708.13.	0.2	0
1003	Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimerâ€™s disease coâ€pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1004	Unfolding the medial temporal lobe to characterize neurodegeneration due to Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1005	Application of histopathologically derived 3D tau burden map as inâ€vivo region of interest for biomarker analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1006	Regional distribution of tau pathology in subfields of hippocampus among phenotypic variants of AD and FTLD-tau.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052392.	0.4	0
1007	Mapping tau burden and neuronal loss in MAPT-associated frontotemporal lobar degeneration.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054141.	0.4	0